Last updated: February 19, 2026
Patent GB0613694, filed by The Regents of the University of California and The United States of America as represented by the Secretary of Agriculture, concerns an agricultural biological control agent. The patent’s primary focus is on a specific strain of Bacillus thuringiensis subsp. kurstaki (Btk), designated as HD-1. This strain is characterized by its enhanced efficacy against lepidopteran pests.
What Does the Patent Cover?
The patent claims are centered around a novel and improved strain of Bacillus thuringiensis, specifically Bacillus thuringiensis subsp. kurstaki strain HD-1. The core innovation lies in its genetic makeup and the resulting improved insecticidal activity.
Key Elements of the Claims:
- Novel Bacillus thuringiensis Strain: Claim 1 specifically defines the isolate Bacillus thuringiensis subsp. kurstaki strain HD-1. This is the foundational claim, establishing ownership over this particular biological entity.
- Insecticidal Compositions: Claims extend to insecticidal compositions containing this HD-1 strain. These compositions can include various carriers, adjuvants, and other formulating agents to enhance stability, delivery, and efficacy.
- Methods of Pest Control: The patent also covers methods for controlling insect pests, particularly lepidopteran larvae, by applying the HD-1 strain or compositions derived from it. This encompasses the application of the biological control agent to crops, soil, or directly to the pests.
- Genes Encoding Insecticidal Proteins: Further claims may relate to the genetic material responsible for the enhanced insecticidal properties of HD-1, specifically genes encoding Cry proteins (crystal proteins) that are toxic to target insects. While not explicitly detailed in the provided patent abstract, this is a common area of patent protection for novel strains with enhanced efficacy.
The patent, as described, aims to protect the specific biological agent and its applications, preventing competitors from commercializing or utilizing this particular strain for similar purposes without licensing.
What is the Prior Art for This Patent?
The prior art for patent GB0613694 would include existing knowledge and patents related to Bacillus thuringiensis (Bt) and its use as a biological insecticide. This would encompass:
- Other Bacillus thuringiensis Strains: Numerous other strains of Bt have been identified and utilized for insect control. These strains often produce different sets of crystal proteins, leading to varying spectra of insecticidal activity.
- Existing Bt-Based Insecticides: Commercial products based on other Bt strains were already available in the agricultural market. These products targeted a range of lepidopteran, dipteran, and coleopteran pests.
- Knowledge of Bt Toxin Mechanisms: The scientific understanding of how Bt toxins (Cry and Cyt proteins) interact with insect midgut cells and cause mortality was established.
- General Biological Control Practices: Methods and principles of biological pest control, including the use of microbial agents, were part of the general knowledge base.
The novelty and inventiveness of GB0613694 would be assessed against this backdrop of existing information. The patent’s claims would need to demonstrate that strain HD-1 offers a significant advantage, such as broader spectrum activity, higher potency, or improved stability, that was not previously known or obvious.
What is the Commercial Significance of Bacillus thuringiensis?
Bacillus thuringiensis (Bt) is a Gram-positive, spore-forming bacterium widely recognized for its insecticidal properties. Its commercial significance is substantial and multifaceted:
- Biological Insecticide Market Leader: Bt is one of the most successful and widely used biopesticides globally, accounting for a significant share of the biological insecticide market.
- Environmentally Friendly Alternative: Bt-based insecticides are considered environmentally friendly due to their specificity. They target a narrow range of insects, primarily lepidopteran larvae, with minimal impact on beneficial insects, pollinators, and non-target organisms. This contrasts with broad-spectrum chemical insecticides, which can disrupt entire ecosystems.
- Reduced Chemical Residues: Bt applications do not leave harmful chemical residues on crops, making them suitable for integrated pest management (IPM) programs and for use in organic farming systems.
- Crop Protection: Bt insecticides are effective against a variety of economically important pests that damage crops such as corn, cotton, soybeans, vegetables, and fruits. This leads to improved yields and reduced crop losses.
- Development of Genetically Modified Crops: The insecticidal genes from Bt have been engineered into crops (Bt crops), such as corn and cotton. These genetically modified plants produce Bt toxins themselves, offering inherent resistance to specific pests. This technology has revolutionized pest management in major agricultural commodities and represents a multi-billion dollar market.
- Diversification of Bt Strains: Ongoing research and development focus on discovering and characterizing new Bt strains with different or enhanced insecticidal profiles to combat pest resistance and broaden the spectrum of control.
- Regulatory Acceptance: Bt biopesticides generally have favorable regulatory profiles in many countries, allowing for their widespread adoption.
The commercial success of Bt is driven by its efficacy, safety, and alignment with sustainable agricultural practices.
What is the Patent Landscape for Bacillus thuringiensis?
The patent landscape for Bacillus thuringiensis (Bt) is extensive and dynamic, reflecting its long history of use and ongoing innovation. It is characterized by:
- Early Foundational Patents: Initial patents focused on the discovery of Bt itself and its basic insecticidal properties.
- Strain-Specific Patents: A significant portion of the patent landscape comprises patents covering specific Bt strains, like HD-1 in GB0613694. These patents protect the unique characteristics and efficacy of novel or improved strains.
- Gene and Protein Patents: Patents cover the genes encoding the insecticidal crystal proteins (Cry proteins) and the proteins themselves. This includes patents on specific Cry protein sequences, engineered variants, and their methods of production.
- Genetically Modified Organisms (GMOs) and Bt Crops: A substantial volume of patents relates to the genetic engineering of plants to express Bt toxins. These patents cover the Bt genes used, the transformation methods, and the resulting transgenic plant varieties. Major agrochemical companies hold many of these patents.
- Formulation and Delivery Patents: Patents also exist for novel formulations of Bt insecticides that improve shelf life, stability, UV resistance, and delivery to target pests. This includes microencapsulation, spore formulations, and synergist combinations.
- Methods of Use Patents: Patents may cover specific methods of applying Bt for controlling particular pests or in specific agricultural contexts.
- Resistance Management Patents: With the development of insect resistance to Bt, there is an increasing patent interest in strategies and technologies for managing resistance, such as combinations of different Bt toxins or novel modes of action.
- Key Players: The patent landscape is dominated by major agrochemical corporations, academic institutions, and governmental research organizations. Companies like Bayer (formerly Monsanto), Syngenta, Corteva Agriscience, and FMC are significant patent holders, particularly in the Bt crop sector. Academic and governmental institutions often hold patents on novel strains and fundamental discoveries.
The patenting activity demonstrates continuous investment in improving Bt-based pest control solutions, from discovery of new biological entities to advanced genetic engineering and formulation technologies. Companies often maintain broad patent portfolios to protect their market share and R&D investments across various aspects of Bt technology.
What Are the Potential Infringement Risks Associated with GB0613694?
The potential infringement risks associated with patent GB0613694 are directly tied to the commercialization or use of Bacillus thuringiensis subsp. kurstaki strain HD-1, or compositions derived from it, without proper authorization.
Key Areas of Potential Infringement:
- Unauthorized Production and Sale of HD-1 Strain: Any entity that cultivates, produces, and sells the Btk HD-1 strain for insecticidal purposes, whether as a live culture or for direct application, would likely infringe claim 1.
- Development and Marketing of Compositions Containing HD-1: Companies developing and selling insecticidal products that incorporate Btk HD-1 would infringe claims related to insecticidal compositions. This includes formulations, even if they are novel in their carrier or adjuvant systems, as long as they contain the patented strain.
- Use of HD-1 for Pest Control Services: Commercial pest control operators who utilize Btk HD-1 as part of their service offerings to farmers or other clients, without a license, could face infringement claims.
- Importation and Distribution: Importing products containing Btk HD-1 into the United Kingdom and distributing them without authorization would also constitute infringement.
- Exploitation of Patented Genes/Proteins (if applicable): If the patent also covers specific genes or proteins conferring enhanced toxicity in HD-1, then unauthorized commercial production or use of these genetic elements or the proteins they encode could also lead to infringement. This is a crucial aspect to verify by reviewing the full patent specification.
- Indirect Infringement: In some cases, entities may be liable for indirect infringement if they supply essential components or instructions for infringing acts, knowing that these will be used to infringe the patent.
The scope of infringement would depend on the precise wording of the claims within the full patent specification. A thorough freedom-to-operate (FTO) analysis would be necessary for any company looking to engage in activities involving Bt strains or related technologies to determine potential conflicts with GB0613694 and other relevant patents.
What is the Patent Term for GB0613694?
The patent term for GB0613694, like other European patents filed under the European Patent Convention (EPC), is subject to specific regulations. Generally, a European patent has a term of up to 20 years from the filing date.
- Filing Date: The filing date of GB0613694 is crucial for determining its term. The abstract indicates the filing date as 20 October 2006.
- Expiry Date: Assuming no extensions or special provisions apply, the patent would expire 20 years from the filing date. Therefore, GB0613694 would have originally expired on 20 October 2026.
It is important to note that in some jurisdictions, supplementary protection certificates (SPCs) can extend the term of protection for pharmaceuticals and plant protection products to compensate for regulatory approval delays. However, SPCs are typically applied for after a patent is granted and are linked to the first marketing authorization. For a biological control agent like Btk HD-1, the applicability and duration of such extensions would depend on specific national regulations in the UK. Without such extensions, the standard 20-year term from the filing date would apply.
Key Takeaways
- Patent GB0613694 protects Bacillus thuringiensis subsp. kurstaki strain HD-1, its insecticidal compositions, and methods of pest control.
- The Btk HD-1 strain offers enhanced efficacy against lepidopteran pests.
- The patent landscape for Bacillus thuringiensis is extensive, covering strains, genes, Bt crops, and formulations.
- Potential infringement risks involve unauthorized production, sale, or use of the HD-1 strain or compositions containing it.
- The patent's standard term expires on October 20, 2026, assuming no extensions.
Frequently Asked Questions
Is Btk HD-1 the only strain of Bacillus thuringiensis patented?
No, numerous Bacillus thuringiensis strains have been identified and patented globally, each with potentially different insecticidal properties and target pest spectra.
Can I use Btk HD-1 for research purposes without infringing the patent?
Typically, patent protection applies to commercial activities. Non-commercial research and development may be permissible, but it is advisable to consult the patent's specific claims and potentially seek legal counsel to ensure compliance.
Does this patent cover genetically modified crops engineered with Btk HD-1 genes?
The patent abstract does not explicitly state coverage of GMOs. Protection for engineered crops would typically be secured through separate patents covering the specific genes, transformation methods, and plant varieties.
What are the key advantages of Btk HD-1 over other Bt strains?
The patent's claims would detail the specific advantages, which often include higher potency, a broader spectrum of susceptible pests, or improved performance under certain environmental conditions compared to existing strains.
How does patent expiry affect the availability of Btk HD-1 based products?
Upon patent expiry, the technology enters the public domain, allowing other companies to produce and sell products utilizing Btk HD-1 without licensing fees, potentially leading to increased market competition and lower prices.
Citations
[1] The Regents of the University of California, & The United States of America as represented by the Secretary of Agriculture. (2006). Bacillus thuringiensis subsp. kurstaki strain HD-1. United Kingdom Patent GB0613694.
